232 related articles for article (PubMed ID: 22887093)
1. Expression of proton-coupled oligopeptide transporter (POTs) in prostate of mice and patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa).
Sun D; Tan F; Fang D; Wang Y; Zeng S; Jiang H
Prostate; 2013 Feb; 73(3):287-95. PubMed ID: 22887093
[TBL] [Abstract][Full Text] [Related]
2. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
3. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
[TBL] [Abstract][Full Text] [Related]
4. The proton-coupled oligopeptide transporters PEPT2, PHT1 and PHT2 mediate the uptake of carnosine in glioblastoma cells.
Oppermann H; Heinrich M; Birkemeyer C; Meixensberger J; Gaunitz F
Amino Acids; 2019 Jul; 51(7):999-1008. PubMed ID: 31073693
[TBL] [Abstract][Full Text] [Related]
5. Detection of pim-1 mRNA in prostate cancer diagnosis.
He HC; Bi XC; Dai QS; Wang SS; Wei HA; Zhong WD; Liu WH; Jiang FN; Liu LS
Chin Med J (Engl); 2007 Sep; 120(17):1491-3. PubMed ID: 17908456
[TBL] [Abstract][Full Text] [Related]
6. The over-expression of Pim-2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B.
Ren K; Gou X; Xiao M; Wang M; Liu C; Tang Z; He W
Prostate; 2013 Sep; 73(13):1462-9. PubMed ID: 23813671
[TBL] [Abstract][Full Text] [Related]
7. Expression profile and functional activity of peptide transporters in prostate cancer cells.
Tai W; Chen Z; Cheng K
Mol Pharm; 2013 Feb; 10(2):477-87. PubMed ID: 22950754
[TBL] [Abstract][Full Text] [Related]
8. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
9. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
[TBL] [Abstract][Full Text] [Related]
10. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
11. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma.
Chandler JD; Williams ED; Slavin JL; Best JD; Rogers S
Cancer; 2003 Apr; 97(8):2035-42. PubMed ID: 12673735
[TBL] [Abstract][Full Text] [Related]
12. Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells.
Grzmil M; Thelen P; Hemmerlein B; Schweyer S; Voigt S; Mury D; Burfeind P
Am J Pathol; 2003 Aug; 163(2):543-52. PubMed ID: 12875974
[TBL] [Abstract][Full Text] [Related]
13. Zinc transporter mRNA expression in the RWPE-1 human prostate epithelial cell line.
Albrecht AL; Somji S; Sens MA; Sens DA; Garrett SH
Biometals; 2008 Aug; 21(4):405-16. PubMed ID: 18097638
[TBL] [Abstract][Full Text] [Related]
14. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
15. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins.
Tang DG; Li L; Chopra DP; Porter AT
Cancer Res; 1998 Aug; 58(15):3466-79. PubMed ID: 9699682
[TBL] [Abstract][Full Text] [Related]
16. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.
Mariani S; Salvatori L; Basciani S; Arizzi M; Franco G; Petrangeli E; Spera G; Gnessi L
J Urol; 2006 Jun; 175(6):2072-7; discussion 2077. PubMed ID: 16697805
[TBL] [Abstract][Full Text] [Related]
17. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic significance of overexpression of Golgi membrane protein 1 in prostate cancer.
Li W; Wang X; Li B; Lu J; Chen G
Urology; 2012 Oct; 80(4):952.e1-7. PubMed ID: 22840862
[TBL] [Abstract][Full Text] [Related]
19. Divergent developmental expression and function of the proton-coupled oligopeptide transporters PepT2 and PhT1 in regional brain slices of mouse and rat.
Hu Y; Xie Y; Keep RF; Smith DE
J Neurochem; 2014 Jun; 129(6):955-65. PubMed ID: 24548120
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
